Korn Ferry, headquartered in Los Angeles, is the world's largest executive search firm, and the largest publicly traded search firm in the United States, with 80 offices in North America, Europe, Asia/Pacific, Latin America, the Middle East and Africa. Wikipedia.
Walker L.L.,Korn Ferry International
Chemical Engineering Progress | Year: 2010
The Brazil, Russia, China and India (BRIC) economies are providing significant opportunities for chemical industry professionals outside the US. Industry experts suggest that professionals seeking such opportunities need to be flexible and adaptable. These measures can help them in taking an expatriate assignment as part of their long-term career development or as a short-term solution to the relative lack of possibilities in the domestic market. They need to be flexible and willing to accept roles and ideas that have never considered before and select assignments that are significant to their career and the organization where they work. Professionals also need to focus on selecting that division or department where they can make the most significant contribution to the growth and development of the organization. Some of the basic factors that will influence the decision to take a job overseas include age of children and partner's career. Source
Denson J.,Korn Ferry International
Trustee : the journal for hospital governing boards | Year: 2012
M.D. Hospitals seeking physician executives first must provide leadership learning opportunities. Source
Korn Ferry International | Date: 2016-03-18
Computer software for use in the development of skills and competencies for businesses, working units, and individuals; computer software for the evaluation and improvement of job performance, career skills and career development for use by individuals and businesses. Printed products, namely, books, cards, placemats and reference materials for use by individuals and businesses to evaluate leadership and managerial aptitudes and skills for the purpose of developing and implementing leadership development and succession plans for businesses, working units and individuals. Executive search, recruitment and placement service; business consultation services in the field of human resources development and management; auditing services for determining business management capabilities; organizational services namely, services for organizing and coordinating talent management; career management, namely, providing career information and career networking services for executives; employment counseling and consultation in the field of executive recruitment. Educational services, namely, conducting classes, workshops, and conferences in the field of human resources and distributing course materials in connection therewith; executive coaching. Providing temporary use of non-downloadable computer programs accessible on a global computer network for use by individuals and businesses for online evaluation, managerial aptitudes and improvement of recruiting, analysis and evaluation skills, job performance and job development, skills for the purpose of developing and implementing leadership development and succession plans for businesses and individuals and on-line instruction manuals sold therewith. Licensing of intellectual property in the field of human resources for the assessment, evaluation, management and development of competencies, job performance, and leadership skills for individuals and organization.
Korn Ferry International | Date: 2015-05-08
Electronic downloadable publications, namely, magazines, written articles, and studies in the field of human resources development and management, executive recruitment, talent management and leadership development. Printed matter, namely, magazines, written articles, manuals, brochures and educational materials in the field of human resources development and management, executive recruitment, talent management and leadership developmen. Business research relating to executive search, recruitment and placement service; outsource service provider in the field of business analytics relating to executive search, recruitment, and placement services; business consultation services in the field of human resources development and management; business research relating to organizing and coordinating talent management; outsource service provider in the field of business analytics relating to organizing and coordinating talent management; business research relating to career information and career networking services for executives; and outsource service provider in the field of business analytics relating to career information and career networking services for executives.
News Article | November 6, 2014
Salix Pharmaceuticals Ltd.’s chief financial officer resigned, and the audit committee will review the way the company characterized wholesale inventory. The stock fell the most in at least 14 years. The board of the company has hired lawyers for the review, Chief Executive Officer Carolyn Logan told investors yesterday on a conference call. Salix shares fell 37 percent to $87.17 at 11:43 a.m., wiping out about $3.3 billion in market value. Inventory held by wholesale distributors of two top Salix drugs, Xifaxan and Apriso, increased to about nine months’ worth as of Sept. 30, the company said. That’s “a level that’s extremely high for this industry,” said Shibani Malhotra, an analyst at Stern Agee Group Inc. “We know what happened, but we don’t know why it happened and how it happened,” Malhotra said. Salix said it will work to cut the inventory to three months by the end of 2016. Salix also said yesterday that Chief Financial Officer Adam Derbyshire would leave the company. Timothy Creech, a senior vice president, will fill in as CFO temporarily, Raleigh, North Carolina-based Salix said in a statement. The company hired Korn Ferry International to conduct a search for a permanent replacement for Derbyshire, who had been at the drugmaker for 14 years. Derbyshire had discussed inventory levels on previous conference calls this year, saying during the first-quarter call in May that Salix was working to make reductions by the end of June. “Ideally, all of our inventories for all of our products would be in that 10- to 12-week range,” he said at the time. The company’s Xifaxan drug is for complications of liver disease, and Apriso treats ulcerative colitis, or chronic inflammation of the colon. The company didn’t say whether Derbyshire’s departure was related to the audit committee review. Its fourth-quarter forecast was far below analysts’ estimates. Excluding some items, earnings will be $1.16 a share, the company said in a separate statement, compared with the $1.95 average projection of analysts compiled by Bloomberg. Net product revenue for the fourth quarter will be about $325 million, compared with the $436 million average estimate, because of high turnover in sales representatives, the company said. Ernst & Young LLP, Salix’s auditor, stands by the company’s 2013 financial statement, the company said. The audit committee review represents a potential setback for the drugmaker just as its merger prospects appeared to suffer a blow. Salix’s potential to be taken over by pharmaceutical companies Actavis Plc and Allergan Inc. has diminished now that those two companies entered active talks on a deal of their own, people with knowledge of the matter said earlier yesterday. Actavis and Allergan have put talks with Salix on hold, said the people, who asked not to be identified because the information is private. Allergan backed away from a deal with Salix in part because due diligence revealed issues with inventory accounting, one person with knowledge of the matter said. Stephen Cohen, a spokesman at Teneo Strategy who works on behalf of Salix, declined to comment on Derbyshire’s departure. A lack of distribution services arrangements with its wholesalers has made it difficult to forecast quarterly revenue, Salix said in the statement. The company is in talks with its main wholesalers to enter such agreements, it said. Salix reported a third-quarter net loss of $88.6 million, or $1.39 a share, compared with a gain of $47.3 million, or 71 cents, a year earlier. Net product revenue climbed 49 percent to $354.7 million. Prescription sales growth should continue to be strong, the company said on its conference call. “I understand some of you may have questions about the audit committee review,” Logan, the CEO, said on the call. “Until that process is complete, we won’t be able to answer questions of the review or its subject matter.”